KRAS and renal cell adenocarcinoma: The Kirsten rat sarcoma viral oncogene homolog (KRAS) can be targeted and downregulated by miR-134 to inhibit the RAS/MAPK/ERK pathway, thereby inhibiting the proliferation and metastasis of RCC cells (Liu Y. et al., 2015).